JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $92
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and increased the price target from $88 to $92.

March 18, 2024 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama has reaffirmed an Overweight rating on Ultragenyx Pharmaceutical and raised the price target to $92.
The increase in price target by a reputable analyst like Anupam Rama from JP Morgan is a strong positive signal for Ultragenyx Pharmaceutical. It suggests a bullish outlook on the stock's future performance, likely due to underlying strengths or anticipated developments within the company. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100